As election day nears, Trump and Harris veer in different directions on pharma; Forbion follows string of startup exits with $2.2B fundraise; Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
Drive your business forward with a corporate subscription to The Wall Street Journal. Bring the most important stories and unrivaled financial reporting to your team today.
Learn more.
Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 14 million decision makers in competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1100 15th Street NW, 4th Floor - (Suite 178), Washington, DC 20005. We value your privacy. We won’t share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
